Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q4 FY2023 Earnings Presentation
24 slides from Lincoln Pharmaceuticals's earnings presentation, 2023
Slide 1: Q4 FY2023 Earnings Presentation
Q4 FY2023 PHARMACEUTICALS LTD Earnings Presentation HEALTHCARE FORALL GROWING IS COMMITEMENT. WE PROCESS. www.lincolnpharma.com
Slide 2: Safe Harbour
SAFEHARBOUR This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relat- ing to Lincoln Pharmaceuticals’ future business developments and economic per
Slide 3: Corporate Overview
CORPORATEOVERVIEW Background Product Portfolio Manufacturing Exports Established in the year 1979, 1700 registered productsand Manufacturing facility at Khatraj, Exports contribute 56.8% in FY23; Lincoln Pharma hasdeveloped another 700 in pipeline. Ahmedabad and Mehsana, Gujarat. Domestic Sales cont
Slide 4: Q4 & FY23 Business Performance & Future Road Map
Q4 & FY23 BUSINESS PERFORMANCE &FUTURE ROAD MAP • Company achieved the milestone of over Rs. 500 crore Revenue and Rs. 100 crore Profit Before Tax for the 1st time in FY23. Company reported total income of Rs. 532.8 crore and PBT of Rs. 100.5 crore. Company recommended dividend of Rs. 1.5 per share.
Slide 5: Q4FY23 Standalone Results
Q4FY23 STANDALONE RESULTS TOTAL INCOME EBITDA NET PROFIT 116.4 19.3 20.5 11.0 12.6 104.4 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Fig (RsCr) Q4 FY2023 Earning Presentation
Slide 6: Performance - Focused Therapeutic Areas
PERFORMANCE - FOCUSEDTHERAPEUTIC AREAS Therapy Area Q4 FY23 Q4 FY22 General Anti Infectives 25.6% 24.2% 23.6% 25.6% 23.2% 24.2% Respiratory Systems 9.3% 8.7% Alimentary Tract andMetabolism 7.3% 7.6% Genito Urinary System and Sex Hormones 1.9% 1.4% 0.3% Musculo-Skeletal System 15.7% 17.8% 1.4% Q4 FY2
Slide 7: Performance Overview
PERFORMANCE OVERVIEW STANDALONE FINANCIAL PERFORMANCE (Rs in Cr.) PARTICULARS Q4 Y-o-Y 12 Months Y-o-Y FY2023 FY2022 Growth (%) FY2023 FY2022 Growth (%) Total Income 116.4 104.4 11.5% 532.8 482.1 10.5% EBITDA 20.5 19.3 6.3% 111.7 105.5 5.9% Profit BeforeTax 17.0 16.8 1.3% 100.5 95.9 4.7% Profit Afte
Slide 8: About Lincoln Pharmaceuticals Ltd
ABOUTLINCOLN PHARMACEUTICALSLTD Providing Affordable And Innovative Medicines For Healthier Lives. VISION To spark a universal attempt to uncover cures of diseases by focused and targeted R&D, through forging strategic alliances both domestically and internationally. MISSION Focused on delivering ou
Slide 9: Key Milestones
KEYMILESTONES 1979 1996/97 2010/11 2016/17 Listed on NSE. Domestic marketexpan- Installed windmill 2.1 Launched nextgeneration Received WHO-GMPfor sion; covered 80% of MW in addition to 6000 progesterone therapy - plant/production unit. India market. KVA in 2009. ProlinSpray. Lincoln was Launched IP
Slide 10: Growth Drivers - Ready for the Next Leap
GROWTHDRIVERS - READY FOR THENEXTLEAP CAPEX Company has successfully completed multiple expansion at Cephalosporin plan at Mehsana, Gujarat. Commercial Production from this plant is expected to start very soon. Cephalosporin Plant is expected to contributed sales of around Rs. 150 crore in next 3 ye
Slide 11: Lincoln Pharmaceuticals Ltd - Financial Overview
LINCOLN PHARMACEUTICALSLTD -FINANCIALOVERVIEW Year Revenue EBITDA Net Profit EPS Share Price FY 23 532.8 111.7 72.9 36.4 338.7 FY 18 367.0 57.7 34.7 17.3 210.3 5 Yrs CAGR 7.7% 14.1% 16.0% 16.0% 10.0% Book Yalue (Per Share) Market Cap (Rs Cr) Net Debt (Rs Cr) 71.1 251 678 623 216 188 450 157 425 135
Slide 12: Business Revenue - Mix
BUSINESS REVENUE - MIX Particulars (Rs.CR) FY 2013 % FY 2017 % FY 2023 % Domestic Sales 145.03 74.50% 246.6 67.40% 220.34 43.2% Export 49.67 25.50% 119.27 32.60% 289.96 56.8% FY13 FY17 FY23 25.50% 32.60% 56.8% 43.2% 67.40% 74.50% DOMESTIC SALES EXPORT Q4 FY2023 Earning Presentation
Slide 13: Global Footprints
GLOBALFOOTPRINTS Presence over 60+ countries in Europe, Latin America, Africa, Asia Pacific, South EastAsia, and 26 states across India. Srinagar Jammu Chandigarh Uttrakhand Ambala Europe: Ghaziabad Delhi France. Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad Indore Raipur Nagpur Cuttack Vijayawada
Slide 14: Research & Development
RESEARCH &DEVELOPMENT NDDS Formulations Introduced First Time In India by Lincoln Anti-Fungal VaginaSpray. Diclofenac RectalSpray. Sildenafil Oral Spray. Ondansetron Hydrochloride Oral Spray (DOMI-UP). Paracetamol 1000mg Programmed ReleaseTablet (PA-12). Micronized Progesterone Vaginal Spray (PROLIN
Slide 15: Innovations - Lincoln Pharma
INNOVATIONS - LINCOLN PHARMA Q4 FY2023 Earning Presentation
Slide 16: New Launches - Domestic Market
NEW LAUNCHES - DOMESTIC MARKET Q4 FY2023 Earning Presentation
Slide 17: New Launches - International Markets
NEW LAUNCHES - INTERNATIONAL MARKETS Q4 FY2023 Earning Presentation
Slide 18: Wide Spectrum of Therapeutic Coverage
WIDE SPECTRUM OF THERAPEUTIC COVERAGE Cough &Cold/ Dermatologist Gyneacological Sterile Ophthalmic Gastro Intestinal Anti Allergic/ Preparation Products Eye Drops/ Range Anti-asthmatics Ointment Yitamins/ Anti-bacterial/ Anti-viral/ Analgesic/ Anti -Malarial M inerals/ Otology Anti-fungal Anti-pyret
Slide 19: Best in Class Facilities – Khatraj, Gujarat
BESTIN CLASS FACILITIES – Khatraj, Gujarat Certification EU-GMP, TGA, WHO-GMP Certified; ISO 9001:2015 Certified. R&D Center Approved by Government of India;Team of 30 plus scientists for R&D. Green Energy Windmill and 1MW Solar Roof installed. Producing 65% of company’s total energy consumption. Do
Slide 20: Best in Class Facilities – Mehsana, Gujarat
BESTIN CLASS FACILITIES – Mehsana, Gujarat WHO-GMP Certified; ISO 9001:2015 Certified. Certification Approved Team of 10 plus scientists for R&D. R&D Center Dosage Forms Produced at Unit 3 OSD and Dry Powder Injection Description Size Annual Capacity Unit Tablet (Compression& Coating) 511 lacs Table
Slide 21: Financial Highlights
FINANCIAL HIGHLIGHTS TOTAL INCOME NET PROFIT 532.8 72.9 69.4 482.1 62.3 428.7 396.3 51.5 FY20 FY21 FY22 FY23 FY20 FY20 FY21 FY21 FY22 FY22 FY23 EBITDA NET WORTH Fig (RsCr) 105.5 111.65 432.9 502.5 92.8 366.4 76.5 304.1 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Q4 FY2023 Earning Presentation
Slide 22: Profitability Ratios
PROFITABILITY RATIOS EBITDA MARGIN PAT MARGIN 21.7% 21.9% 14.5% 14.4% 21.0% 13.0% 13.7% 19.3% FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 ROCE RONW 22.6% 16.9% 17.0% 22.0% 21.9% 16.0% 19.9% 14.5% FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Q4 FY2023 Earning Presentation
Slide 23: Share Holding Information
SHARE HOLDINGINFORMATION Particulars March 2023 March 2022 Investor Category No of Shareholders No of Shares Held Holding (%) No ofShareholders No of Shares Held Holding (%) Promoter Group 27 94,14,112 47.00% 29 84,22,173 42.05% Public Holding 29,061 1,06,15,616 53.00% 32,418 1,16,07,555 57.95% Tota
Slide 24: Location
LOCATION Corporate Office Lincoln House B/h Satyam Complex, Science City Road, Sola Ahmedabad - 380060,Gujarat, India. Phone: +91 - 79 - 4107 8000 l Fax: +91- 79 - 4107 8062 Email: info@lincolnpharma.com Web: www.lincolnpharma.com CIN: L24230GJ1995PLC024288 Darshit Shah Gopal Modi CFO, Lincoln Pharm
Lincoln Pharmaceuticals — Q4 FY2023 Earnings Presentation on 6ix